Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis
Abstract
Background The involvement of Mucosal Associated Invariant T (MAIT) cells, which are anti-microbial semi-invariant T cells, remains elusive in Multiple Sclerosis (MS). Objective Deciphering the potential involvement of MAIT cells in the MS inflammatory process. Methods By flow cytometry, blood MAIT cells from similar cohorts of MS patients and healthy volunteers (HV) were compared for frequency, phenotype, activation potential after in vitro TCR engagement by bacterial ligands and transmigration abilities through an in vitro model of blood-brain barrier. MS CNS samples were also studied by immunofluorescent staining and quantitative PCR. Results and conclusion Blood MAIT cells from relapsing-remitting MS patients and HV presented similar frequency, ex vivo effector phenotype and activation abilities. MAIT cells represented 0.5% of the total infiltrating T cells on 39 MS CNS lesions. This is low as compared to blood frequency (p<0.001), but consistent with their low transmigration rate. Finally, transcriptional over-expression of MR1 - which presents cognate antigens to MAIT cells - and of the activating cytokines IL-18 and IL-23 was evidenced in MS lesions, suggesting that the CNS microenvironment is suited to activate the few infiltrating MAIT cells. Taken together, these data place MAIT cells from MS patients as minor components of the inflammatory pathological process.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In multiple sclerosis, the number of MAIT cells is elevated, with MAIT cells producing higher levels of pro-inflammatory cytokines, concomitant with an increase in MR1 expression.
“Of note, in multiple sclerosis (MS), the number of MAIT cells is elevated, with MAIT cells producing a higher level of pro-inflammatory cytokines, concomitant with an increase in MR1 expression [10, 13].”
From Control of the temporal development of Alzheimer’s disease pathology by the MR1/MAIT cell axis (2023) · cites this paper as [13]
MR1 level directly correlates with a poor outcome in MS and glioma.
“Moreover, its level directly correlates with a poor outcome in MS and glioma [13, 15].”
From Control of the temporal development of Alzheimer’s disease pathology by the MR1/MAIT cell axis (2023) · cites this paper as [13]
Cites
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works
Piccio, L., Rossi, B., Scarpini, E., Laudanna, C., Giagulli, C., Issekutz, A. C., Vestweber, D., Butcher, E. C., & Constantin, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.4.1940 · Cited by 245 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380 · see citing works
Mucosal-associated invariant T cells and disease
Toubal, A., Nel, I., Lotersztajn, S., & Lehuen, A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0191-y · Cited by 300 · see citing works
Böttcher, K., Rombouts, K., Saffioti, F., Roccarina, D., Rosselli, M., Hall, A., Luong, T., Tsochatzis, E. A., Thorburn, D., & Pinzani, M. (2018) · Hepatology · doi:10.1002/hep.29782 · Cited by 183 · see citing works
Control of the temporal development of Alzheimer’s disease pathology by the MR1/MAIT cell axis
Wyatt-Johnson, S. K., Kersey, H. N., Codocedo, J. F., Newell, K. L., Landreth, G. E., Lamb, B. T., Oblak, A. L., & Brutkiewicz, R. R. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02761-6 · Cited by 22 · see citing works
- Authors
- Salou, M., Nicol, B., Garcia, A., Baron, D., Michel, L., Elong-Ngono, A., Hulin, P., Nedellec, S., Jacq-Foucher, M., Le Frère, F., Jousset, N., Bourreille, A., Wiertlewski, S., Soulillou, J.-P., Brouard, S., Nicot, A. B., Degauque, N., & Laplaud, D.-A.
- Affiliations
- Inserm (FR)
- Structure Fédérative de Recherche Bonamy (FR)
- Corresponding author
- Laplaud, David-Axel
- ORCID
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 166-167
- Pages
- 1-11
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W2326249228
- Cited by
- 70
- References
- 2
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 12 · 2023: 7 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 2
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- ARSEP Foundation
- ANTARES Association
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- mucosal-associated invariant T cells, multiple sclerosis, relapsing-remitting multiple sclerosis, MR1, IL-18, IL-23, central nervous system lesions, T cell activation, neuroinflammation
- MeSH terms
- Mucosal-Associated Invariant T Cells, Adult, Blood-Brain Barrier, Brain, Cell Movement, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Models, Biological, Receptors, Antigen, T-Cell, Histocompatibility Antigens Class I, Minor Histocompatibility Antigens, Case-Control Studies, Immunophenotyping, Immunity, Mucosal, Interleukin-18, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Interleukin-23
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review